AUROBINDO PHARMA LTD. Completes US FDA Audit with 10 Observations at Apitoria Pharma Subsidiary

AUROBINDO PHARMA LTD. has completed a US FDA audit at Unit II of Apitoria Pharma Private Limited, its wholly owned subsidiary. The audit took place from September 23 to 27, 2024, at an API manufacturing facility in Telangana, India. The inspection resulted in 10 observations, all of procedural nature. The company will respond within the stipulated time and keep stock exchanges informed of any further developments. The delay in intimation is due to the non-availability of senior technical team to review the observations.